Genomic Health (GHDX) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Genomic Health Inc. (GHDX) PT Lowered to $69 at Needham & Company
May 9, 2019 7:42 AM EDTNeedham & Company analyst Stephen Unger lowered the price target on Genomic Health Inc. (NASDAQ: GHDX) to $69.00 (from $97.00) while maintaining a Strong Buy rating following the company's 1Q report. Unger was somewhat surprised by the negative reaction to what he views as strong 1Q19 results,... More



